Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine

In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.

Automated summary

In vitro testing of serum samples from CoronaVac vaccine recipients showed that neutralizing antibodies provided short-term protection against the original virus strain and limited protection against variants of concern. These findings support the use of vaccine boosters, particularly in regions where variants of concern are circulating.